Federal contractor · ROCKVILLE, MD

MIRECULE, INC.

No contract obligations recorded for MIRECULE, INC. in FY2026. Since FY2018: $305K. It also received $608.8K in federal grants and other assistance in FY2026.

Obligations · FY2026
$0
New awards
0
Sole-source
—
Single offer
—
UEI
D2DDKPAALJR3
Parent company
MIRECULE INC
Small business
Open in the contracts explorerRelationship graph

Spending by fiscal year

Obligations per federal fiscal year (October–September).

  1. 305KFY2018
  2. 0FY2019
  3. 0FY2023

Top buying agencies

Obligations in FY2026.

No contract obligations recorded for MIRECULE, INC. in FY2026.

What was bought · Where the work was performed

Obligations in FY2026.

What was bought

Where the work was performed

Integrity signals

Shares of the year's obligations, next to the country's.

Federal grants & assistance received

Grants, loans (counted at their subsidy cost), direct payments and insurance, by fiscal year of the action (USAspending.gov, FABS). Reported apart from contracts and never added to them.

MIRECULE, INC. received $608.8K in federal assistance in FY2026, on 2 actions (0 new awards), −71% vs FY2025. Its largest program was 93.853 · Extramural Research Programs in the Neurosciences and Neurological Disorders ($608.8K).

Assistance · FY2026
$608.8K
New awards
0
Actions
2
Since FY2021
$6.5M

Assistance by fiscal year

  1. 1.4MFY2021
  2. 368.7KFY2022
  3. 0FY2023
  4. 2MFY2024
  5. 2.1MFY2025
  6. 608.8KFY2026

By type

  1. Grants$608.8K100%

Top programs

  1. 93.853 · Extramural Research Programs in the Neurosciences and Neurological Disorders$608.8K100%

Awarding agencies

  1. National Institutes of Health$608.8K100%
    Department of Health and Human Services

Largest awards

  1. A NOVEL RNA THERAPEUTICS PLATFORM TO TREAT FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY AND OTHER NEUROMUSCULAR DISORDERS - ABSTRACT: IN THIS…$3.7M
    93.853 · Extramural Research Programs in the Neurosciences and Neurological Disorders· National Institutes of Health· Project grant· Sep 21, 2021 – Sep 4, 2026· R44NS119147
  2. DEVELOPMENT OF AN ANTIBODY-OLIGONUCLEOTIDE CONJUGATE FOR TREATMENT OF HEAD AND NECK SQUAMOUS CELL CARCINOMA - ABSTRACT: IN THIS DIRECT TO…$1.8M
    93.395 · Cancer Treatment Research· National Institutes of Health· Project grant· Sep 18, 2024 – Aug 21, 2026· R44CA291527

Source: Federal financial assistance transactions (Financial Assistance Broker Submission) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 8, 2026, loaded Oct 8, 2026 · FY2021–FY2026.

Source: Federal contract transactions (Federal Procurement Data System) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 7, 2026, loaded Oct 7, 2026.